Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis.

Free ME, Stember KG, Hess JJ, McInnis EA, Lardinois O, Hogan SL, Hu Y, Mendoza C, Le AK, Guseman AJ, Pilkinton MA, Bortone DS, Cowens K, Sidney J, Karosiene E, Peters B, James E, Kwok WW, Vincent BG, Mallal SA, Jennette JC, Ciavatta DJ, Falk RJ.

J Autoimmun. 2019 Aug 2:102306. doi: 10.1016/j.jaut.2019.102306. [Epub ahead of print]

PMID:
31383567
2.

Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Wu EY, McInnis EA, Boyer-Suavet S, Mendoza CE, Aybar LT, Kennedy KB, Poulton CJ, Henderson CD, Hu Y, Hogan SL, Hu P, Xiao H, Nachman PH, Jennette JC, Falk RJ, Bunch DO.

Arthritis Rheumatol. 2019 Jun 19. doi: 10.1002/art.41011. [Epub ahead of print]

PMID:
31215772
3.

Understanding Long-term Remission Off Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Hogan SL, Nachman PH, Poulton CJ, Hu Y, Blazek LN, Free ME, Jennette JC, Falk RJ.

Kidney Int Rep. 2019 Jan 28;4(4):551-560. doi: 10.1016/j.ekir.2019.01.004. eCollection 2019 Apr.

4.

Economic and objective burden of caregiving on informal caregivers of patients with systemic vasculitis.

Nguyen JT, Roberts C, Thorpe CT, Thorpe JM, Hogan SL, McGregor J, Geryk L, Carpenter DM.

Musculoskeletal Care. 2019 Jun;17(2):282-287. doi: 10.1002/msc.1394. Epub 2019 Mar 22.

PMID:
30901158
5.

Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study.

Chanouzas D, McGregor JAG, Nightingale P, Salama AD, Szpirt WM, Basu N, Morgan MD, Poulton CJ, Draibe JB, Krarup E, Dospinescu P, Dale JA, Pendergraft WF, Lee K, Egfjord M, Hogan SL, Harper L.

BMC Nephrol. 2019 Feb 18;20(1):58. doi: 10.1186/s12882-019-1226-0.

6.

Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients.

Ibrahim ME, Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant CL, Bowles DW, George B, Wen X, Buckley B, Aleksunes L, Joy MS.

Eur J Clin Pharmacol. 2019 Jan;75(1):51-57. doi: 10.1007/s00228-018-2552-z. Epub 2018 Sep 15.

PMID:
30220072
7.

Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.

Weiner M, Bjørneklett R, Hrušková Z, Mackinnon B, Poulton CJ, Sindelar L, Mohammad AJ, Eriksson P, Gesualdo L, Geetha D, Crnogorac M, Jayne D, Hogan SL, Geddes C, Tesar V, Aasarød K, Segelmark M.

Nephrol Dial Transplant. 2019 Feb 1;34(2):301-308. doi: 10.1093/ndt/gfy106.

8.

Segmental Sclerosis and Extracapillary Hypercellularity Predict Diabetic ESRD.

Mottl AK, Gasim A, Schober FP, Hu Y, Dunnon AK, Hogan SL, Jennette JC.

J Am Soc Nephrol. 2018 Feb;29(2):694-703. doi: 10.1681/ASN.2017020192. Epub 2017 Nov 27.

9.

Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey.

O'Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC.

Nephrol Dial Transplant. 2018 Apr 1;33(4):661-669. doi: 10.1093/ndt/gfx189.

10.

Healthcare utilization and expenditures for United States Medicare beneficiaries with systemic vasculitis.

Thorpe CT, Thorpe JM, Jiang T, Atkinson D, Kang Y, Schleiden LJ, Carpenter DM, McGregor JAG, Hogan SL.

Semin Arthritis Rheum. 2018 Feb;47(4):507-519. doi: 10.1016/j.semarthrit.2017.08.005. Epub 2017 Aug 10.

11.

Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin.

Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant C, Bowles DW, George B, Wen X, Aleksunes LM, Joy MS.

Int J Mol Sci. 2017 Jun 22;18(7). pii: E1333. doi: 10.3390/ijms18071333.

12.

Temporal and Demographic Trends in Glomerular Disease Epidemiology in the Southeastern United States, 1986-2015.

O'Shaughnessy MM, Hogan SL, Poulton CJ, Falk RJ, Singh HK, Nickeleit V, Jennette JC.

Clin J Am Soc Nephrol. 2017 Apr 3;12(4):614-623. doi: 10.2215/CJN.10871016. Epub 2017 Mar 21.

13.

Examining whether the information-motivation-behavioral skills model predicts medication adherence for patients with a rare disease.

Alexander DS, Hogan SL, Jordan JM, DeVellis RF, Carpenter DM.

Patient Prefer Adherence. 2017 Jan 12;11:75-83. doi: 10.2147/PPA.S115272. eCollection 2017.

14.

Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity.

George B, Wen X, Mercke N, Gomez M, O'Bryant C, Bowles DW, Hu Y, Hogan SL, Joy MS, Aleksunes LM.

Clin Pharmacol Ther. 2017 Apr;101(4):510-518. doi: 10.1002/cpt.606. Epub 2017 Feb 14.

15.

Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis.

Jones BE, Yang J, Muthigi A, Hogan SL, Hu Y, Starmer J, Henderson CD, Poulton CJ, Brant EJ, Pendergraft WF 3rd, Jennette JC, Falk RJ, Ciavatta DJ.

J Am Soc Nephrol. 2017 Apr;28(4):1175-1187. doi: 10.1681/ASN.2016050548. Epub 2016 Nov 7.

16.

Histone modification signature at myeloperoxidase and proteinase 3 in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

Yang J, Ge H, Poulton CJ, Hogan SL, Hu Y, Jones BE, Henderson CD, McInnis EA, Pendergraft WF 3rd, Jennette JC, Falk RJ, Ciavatta DJ.

Clin Epigenetics. 2016 Aug 12;8:85. doi: 10.1186/s13148-016-0251-0. eCollection 2016.

17.

Distinguishing the Signals From the Noise: Can Epidemiologic Studies Inform Our Understanding of Glomerular Disease?

O'Shaughnessy MM, Hogan SL.

Am J Kidney Dis. 2016 Oct;68(4):503-507. doi: 10.1053/j.ajkd.2016.05.009. No abstract available.

PMID:
27664473
18.

The Relationship Between Social Support, Social Constraint, and Psychological Adjustment for Patients with Rare Autoimmune Disease.

Carpenter DM, Thorpe CT, Alexander DS, Sage AJ, Lewis M, Hogan SL, Geryk LL, DeVellis RF.

Curr Rheumatol Rev. 2016;12(3):232-238.

19.

Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS.

Laurin LP, Gasim AM, Derebail VK, McGregor JG, Kidd JM, Hogan SL, Poulton CJ, Detwiler RK, Jennette JC, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1752-1759. doi: 10.2215/CJN.13091215. Epub 2016 Jul 21.

20.

Patients with primary membranous nephropathy are at high risk of cardiovascular events.

Lee T, Derebail VK, Kshirsagar AV, Chung Y, Fine JP, Mahoney S, Poulton CJ, Lionaki S, Hogan SL, Falk RJ, Cattran DC, Hladunewich M, Reich HN, Nachman PH.

Kidney Int. 2016 May;89(5):1111-1118. doi: 10.1016/j.kint.2015.12.041. Epub 2016 Feb 26.

21.

Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS.

Laurin LP, Gasim AM, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Foster BJ, Nachman PH.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):386-94. doi: 10.2215/CJN.07110615. Epub 2016 Feb 16.

22.

Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease.

Rhee RL, Hogan SL, Poulton CJ, McGregor JA, Landis JR, Falk RJ, Merkel PA.

Arthritis Rheumatol. 2016 Jul;68(7):1711-20. doi: 10.1002/art.39614.

23.

Complete Remission in the Nephrotic Syndrome Study Network.

Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):81-9. doi: 10.2215/CJN.02560315. Epub 2015 Dec 10.

24.

Clinical Features of Reported Ethylene Glycol Exposures in the United States.

Jobson MA, Hogan SL, Maxwell CS, Hu Y, Hladik GA, Falk RJ, Beuhler MC, Pendergraft WF 3rd.

PLoS One. 2015 Nov 13;10(11):e0143044. doi: 10.1371/journal.pone.0143044. eCollection 2015.

25.

Pesticide exposure and end-stage renal disease risk among wives of pesticide applicators in the Agricultural Health Study.

Lebov JF, Engel LS, Richardson D, Hogan SL, Sandler DP, Hoppin JA.

Environ Res. 2015 Nov;143(Pt A):198-210. doi: 10.1016/j.envres.2015.10.002. Epub 2015 Oct 24.

26.

Pesticide use and risk of end-stage renal disease among licensed pesticide applicators in the Agricultural Health Study.

Lebov JF, Engel LS, Richardson D, Hogan SL, Hoppin JA, Sandler DP.

Occup Environ Med. 2016 Jan;73(1):3-12. doi: 10.1136/oemed-2014-102615. Epub 2015 Jul 15.

27.

The relationship between peer support, medication adherence, and quality of life among patients with vasculitis.

Alexander DS, Hogan SL, Jordan JM, DeVellis RF, Carpenter DM.

Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-185-6. Epub 2015 May 26. No abstract available.

28.

Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis.

Bunch DO, Mendoza CE, Aybar LT, Kotzen ES, Colby KR, Hu Y, Hogan SL, Poulton CJ, Schmitz JL, Falk RJ, Nachman PH, Pendergraft WF, McGregor JG.

Ann Rheum Dis. 2015 Sep;74(9):1784-6. doi: 10.1136/annrheumdis-2014-206756. Epub 2015 Apr 30. No abstract available.

29.

A population-based study of prevalence and risk factors of chronic kidney disease in León, Nicaragua.

Lebov JF, Valladares E, Peña R, Peña EM, Sanoff SL, Cisneros EC, Colindres RE, Morgan DR, Hogan SL.

Can J Kidney Health Dis. 2015 Feb 24;2:6. doi: 10.1186/s40697-015-0041-1. eCollection 2015.

30.

Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function.

McGregor JG, Negrete-Lopez R, Poulton CJ, Kidd JM, Katsanos SL, Goetz L, Hu Y, Nachman PH, Falk RJ, Hogan SL.

Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i171-81. doi: 10.1093/ndt/gfv045.

31.

Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.

McGregor JG, Hogan SL, Kotzen ES, Poulton CJ, Hu Y, Negrete-Lopez R, Kidd JM, Katsanos SL, Bunch DO, Nachman PH, Falk RJ.

Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i123-31. doi: 10.1093/ndt/gfv076.

32.

What Everybody is Doing but No One is Talking About: Use of Complementary and Alternative Medicine in the ANCA Associated Vasculitis Population.

Berg EA, McGregor JG, Burkart ME, Poulton CJ, Hu Y, Falk RJ, Hogan SL.

J Autoimmune Dis Rheumatol. 2014 Nov 1;2(3):74-91.

33.

PTPN22 R620W polymorphism and ANCA disease risk in white populations: a metaanalysis.

Cao Y, Liu K, Tian Z, Hogan SL, Yang J, Poulton CJ, Falk RJ, Li W.

J Rheumatol. 2015 Feb;42(2):292-9. doi: 10.3899/jrheum.131430. Epub 2014 Dec 1.

34.

Reduced CD5(+) CD24(hi) CD38(hi) and interleukin-10(+) regulatory B cells in active anti-neutrophil cytoplasmic autoantibody-associated vasculitis permit increased circulating autoantibodies.

Aybar LT, McGregor JG, Hogan SL, Hu Y, Mendoza CE, Brant EJ, Poulton CJ, Henderson CD, Falk RJ, Bunch DO.

Clin Exp Immunol. 2015 May;180(2):178-88. doi: 10.1111/cei.12483.

35.

Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure.

Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, Lionaki S, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2014 May;9(5):905-13. doi: 10.2215/CJN.08290813. Epub 2014 Feb 27.

36.

A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis.

Joy MS, Roberts BV, Wang J, Hu Y, Hogan SL, Falk RJ.

Int J Clin Pharmacol Ther. 2014 Apr;52(4):303-13. doi: 10.5414/CP201972.

37.

Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose.

Derebail VK, Lacson EK Jr, Kshirsagar AV, Key NS, Hogan SL, Hakim RM, Mooney A, Jani CM, Johnson C, Hu Y, Falk RJ, Lazarus JM.

J Am Soc Nephrol. 2014 Apr;25(4):819-26. doi: 10.1681/ASN.2013060575. Epub 2014 Jan 23.

38.

Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans.

Geetha D, Poulton CJ, Hu Y, Seo P, McGregor JA, Falk RJ, Hogan SL.

Semin Arthritis Rheum. 2014 Jun;43(6):778-83. doi: 10.1016/j.semarthrit.2013.11.011. Epub 2013 Dec 4.

39.

Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy.

Lee T, Biddle AK, Lionaki S, Derebail VK, Barbour SJ, Tannous S, Hladunewich MA, Hu Y, Poulton CJ, Mahoney SL, Charles Jennette J, Hogan SL, Falk RJ, Cattran DC, Reich HN, Nachman PH.

Kidney Int. 2014 Jun;85(6):1412-20. doi: 10.1038/ki.2013.476. Epub 2013 Dec 11.

40.

Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population.

Free ME, Bunch DO, McGregor JA, Jones BE, Berg EA, Hogan SL, Hu Y, Preston GA, Jennette JC, Falk RJ, Su MA.

Arthritis Rheum. 2013 Jul;65(7):1922-33. doi: 10.1002/art.37959.

41.

Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis.

Roth AJ, Ooi JD, Hess JJ, van Timmeren MM, Berg EA, Poulton CE, McGregor J, Burkart M, Hogan SL, Hu Y, Winnik W, Nachman PH, Stegeman CA, Niles J, Heeringa P, Kitching AR, Holdsworth S, Jennette JC, Preston GA, Falk RJ.

J Clin Invest. 2013 Apr;123(4):1773-83. doi: 10.1172/JCI65292. Epub 2013 Mar 15.

42.

Pathways to renal biopsy and diagnosis among patients with ANCA small-vessel vasculitis.

Poulton CJ, Nachman PH, Hu Y, McGregor JG, Jennette JC, Falk RJ, Hogan SL.

Clin Exp Rheumatol. 2013 Jan-Feb;31(1 Suppl 75):S32-7. Epub 2013 Jan 23.

43.

Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach.

Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PX, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ, Lienczewski CC, Adler SG, Appel GB, Cattran DC, Choi MJ, Contreras G, Dell KM, Fervenza FC, Gibson KL, Greenbaum LA, Hernandez JD, Hewitt SM, Hingorani SR, Hladunewich M, Hogan MC, Hogan SL, Kaskel FJ, Lieske JC, Meyers KE, Nachman PH, Nast CC, Neu AM, Reich HN, Sedor JR, Sethna CB, Trachtman H, Tuttle KR, Zhdanova O, Zilleruelo GE, Kretzler M.

Kidney Int. 2013 Apr;83(4):749-56. doi: 10.1038/ki.2012.428. Epub 2013 Jan 16.

44.

Predictors of medication non-adherence for vasculitis patients.

Carpenter DM, Hogan SL, Devellis RF.

Clin Rheumatol. 2013 May;32(5):649-57. doi: 10.1007/s10067-013-2164-z. Epub 2013 Jan 12.

45.

Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2013 Mar;8(3):382-91. doi: 10.2215/CJN.03950412. Epub 2013 Jan 4.

46.

Normoalbuminuric diabetic kidney disease in the U.S. population.

Mottl AK, Kwon KS, Mauer M, Mayer-Davis EJ, Hogan SL, Kshirsagar AV.

J Diabetes Complications. 2013 Mar-Apr;27(2):123-7. doi: 10.1016/j.jdiacomp.2012.09.010. Epub 2012 Nov 24.

47.

Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.

Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, Nachman PH, Jennette JC, Falk RJ.

Arthritis Rheum. 2012 Oct;64(10):3452-62. doi: 10.1002/art.34562.

48.

High basal activity of the PTPN22 gain-of-function variant blunts leukocyte responsiveness negatively affecting IL-10 production in ANCA vasculitis.

Cao Y, Yang J, Colby K, Hogan SL, Hu Y, Jennette CE, Berg EA, Zhang Y, Jennette JC, Falk RJ, Preston GA.

PLoS One. 2012;7(8):e42783. doi: 10.1371/journal.pone.0042783. Epub 2012 Aug 3.

49.

A clinical tool to measure the components of health-care transition from pediatric care to adult care: the UNC TR(x)ANSITION scale.

Ferris ME, Harward DH, Bickford K, Layton JB, Ferris MT, Hogan SL, Gipson DS, McCoy LP, Hooper SR.

Ren Fail. 2012;34(6):744-53. doi: 10.3109/0886022X.2012.678171. Epub 2012 May 14.

PMID:
22583152
50.

Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis.

Joy MS, La M, Wang J, Bridges AS, Hu Y, Hogan SL, Frye RF, Blaisdell J, Goldstein JA, Dooley MA, Brouwer KL, Falk RJ.

Br J Clin Pharmacol. 2012 Sep;74(3):445-55. doi: 10.1111/j.1365-2125.2012.04223.x.

Supplemental Content

Loading ...
Support Center